| Literature DB >> 23227803 |
Mariëlle M Beckers1, Gerwin Huls.
Abstract
The prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow-up, the patient has no detectable disease. Lenalidomide was well tolerated without side-effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23227803 DOI： 10.1111/ejh.12053
Source DB: PubMed Journal: Eur J Haematol ISSN： 0902-4441 Impact factor: 2.997